S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
Log in
ASX:CUV

Clinuvel Pharmaceuticals Limited (CUV.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$23.00
MA: A$23.00
A$23.00
52-Week Range N/A
Volume124,193 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend Yield0.12%
BetaN/A
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering drugs for the treatment of patients with severe genetic and skin disorders worldwide. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity; and PRÃNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited for launching SCENESSE under a named patient program for the treatment of patients with EPP in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.

MarketRank

Overall MarketRank

0.65 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 3 9660 4900
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$32.57 million
Book ValueA$1.49 per share

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

Receive CUV News and Ratings via Email

Sign-up to receive the latest news and ratings for CUV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Clinuvel Pharmaceuticals Limited (CUV.AX) (ASX:CUV) Frequently Asked Questions

What stocks does MarketBeat like better than Clinuvel Pharmaceuticals Limited (CUV.AX)?

Wall Street analysts have given Clinuvel Pharmaceuticals Limited (CUV.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Clinuvel Pharmaceuticals Limited (CUV.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How often does Clinuvel Pharmaceuticals Limited (CUV.AX) pay dividends? What is the dividend yield for Clinuvel Pharmaceuticals Limited (CUV.AX)?

Clinuvel Pharmaceuticals Limited (CUV.AX) announced a Final dividend on Friday, August 28th. Investors of record on Friday, September 18th will be paid a dividend of 0.025 per share on Friday, September 18th. This represents a yield of 0.12%. The ex-dividend date of this dividend is Thursday, September 3rd.
View Clinuvel Pharmaceuticals Limited (CUV.AX)'s dividend history
.

Is Clinuvel Pharmaceuticals Limited (CUV.AX) a good dividend stock?

Clinuvel Pharmaceuticals Limited (CUV.AX) pays an annual dividend of A$0.03 per share and currently has a dividend yield of 0.12%. The dividend payout ratio of Clinuvel Pharmaceuticals Limited (CUV.AX) is 9.09%. This payout ratio is at a healthy, sustainable level, below 75%.
View Clinuvel Pharmaceuticals Limited (CUV.AX)'s dividend history.

Who are some of Clinuvel Pharmaceuticals Limited (CUV.AX)'s key competitors?

What other stocks do shareholders of Clinuvel Pharmaceuticals Limited (CUV.AX) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clinuvel Pharmaceuticals Limited (CUV.AX) investors own include Zynga (ZNGA), Worldpay (WP), VolitionRx (VNRX), REA Group Limited (REA.AX) (REA), CSL Limited (CSL.AX) (CSL), Cochlear Limited (COH.AX) (COH), Catabasis Pharmaceuticals (CATB) and Afterpay Limited (APT.AX) (APT).

Who are Clinuvel Pharmaceuticals Limited (CUV.AX)'s key executives?

Clinuvel Pharmaceuticals Limited (CUV.AX)'s management team includes the following people:
  • Dr. Philippe Jacques Wolgen M.B.A., MBA, M.D., CEO, MD & Director (Age 58, Pay $1.73M)
  • Mr. Darren M. Keamy, CFO & Company Sec. (Age 48, Pay $372.08k)
  • Dr. Dennis J. Wright, Chief Scientific Officer
  • Mr. Malcolm Bull, Head of Investor Relations
  • Lachlan Hay, Gen. Mang. of Europe

What is Clinuvel Pharmaceuticals Limited (CUV.AX)'s stock symbol?

Clinuvel Pharmaceuticals Limited (CUV.AX) trades on the ASX under the ticker symbol "CUV."

How big of a company is Clinuvel Pharmaceuticals Limited (CUV.AX)?

Clinuvel Pharmaceuticals Limited (CUV.AX) has a market capitalization of $0.00 and generates $32.57 million in revenue each year.

What is Clinuvel Pharmaceuticals Limited (CUV.AX)'s official website?

The official website for Clinuvel Pharmaceuticals Limited (CUV.AX) is www.clinuvel.com.

How can I contact Clinuvel Pharmaceuticals Limited (CUV.AX)?

The company can be reached via phone at 61 3 9660 4900.

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.